Pure Global
NCT06315335

A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese Participants

A SINGLE CENTER, RANDOMIZED, INVESTIGATOR- AND PARTICIPANT-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ETHNOBRIDGING PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE-DOSE OF UCB9741 IN HEALTHY CAUCASIAN AND JAPANESE PARTICIPANTS
UCB Biopharma SRL·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
UCB9741
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
UCB Biopharma SRL
Funder
UCB Pharma
Timeline & enrollment
Phase
Phase 1
Start date
Jul 01, 2024
End date
Jul 29, 2025
Enrollment
50 participants
Primary outcome

Occurrence of TEAEs,Occurrence of treatment-emergent SAEs

Summary

The purpose of the study is investigate the safety, tolerability and pharmacokinetic of
 UCB9741 after 2 dose strengths administered subcutaneous as a single-dose in healthy
 Caucasian and Japanese participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06315335
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06315335 through Pure Global AI's free database. This Phase 1 trial is sponsored by UCB Biopharma SRL and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.